Compare PROF & PNNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROF | PNNT |
|---|---|---|
| Founded | N/A | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.1M | 285.3M |
| IPO Year | 2017 | 2007 |
| Metric | PROF | PNNT |
|---|---|---|
| Price | $6.24 | $4.63 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 5 |
| Target Price | ★ $12.00 | $5.85 |
| AVG Volume (30 Days) | 215.8K | ★ 761.5K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 21.24% |
| EPS Growth | ★ 25.89 | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $16,098,000.00 | N/A |
| Revenue This Year | $92.40 | N/A |
| Revenue Next Year | $64.10 | N/A |
| P/E Ratio | ★ $4.45 | $13.14 |
| Revenue Growth | ★ 50.73 | N/A |
| 52 Week Low | $3.92 | $4.29 |
| 52 Week High | $8.95 | $7.53 |
| Indicator | PROF | PNNT |
|---|---|---|
| Relative Strength Index (RSI) | 51.08 | 47.39 |
| Support Level | $5.86 | N/A |
| Resistance Level | $7.02 | $4.93 |
| Average True Range (ATR) | 0.50 | 0.13 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 65.29 | 78.75 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.